Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00306878
Status:
COMPLETED
Last Update Posted:
2011-04-13
First Post:
2006-03-23
Brief Title:
Phase I Study of BMS-188667 CTLA4Ig in Patients With Psoriasis Vulgaris
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Phase I Study of BMS-188667 CTLA4Ig in Patients With Psoriasis Vulgaris
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical research study is to determine the safety pharmacokinetics immunogenicity in humans the recovery time required from the biologic effects and the optimal biologic dose range of BMS188667 CTLA4Ig
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None